Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin Data [Yahoo! Finance]
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: Yahoo! Finance
On April 16, 2026, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) will be presented on April 22 at the American Academy of Neurology Annual Meeting in Chicago. The data support the selection of the 10 mg dose for Phase 3 development. In the study, pilavapadin 10 mg demonstrated a nominally significant reduction in Average Pain at Week 8 versus placebo, along with consistent improvements in Worst and Least Daily Pain based on the Brief Pain Inventory-DPN. The treatment was generally well tolerated, with completion rates similar to placebo and few discontinuations due to adverse events. At the same conference, the company will also present preclinical findings evaluating pilavapadin's impact on spasticity-related endpoints in models of multiple sclerosis and spinal cord injury. Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin Data Last month, Lexicon an
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Lexicon to Present Data at the American Academy of Neurology (AAN) Annual MeetingGlobeNewswire
- Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & ExpoGlobeNewswire
- Lexicon Pharmaceuticals (LXRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851GlobeNewswire
LXRX
Earnings
- 3/5/26 - Beat
LXRX
Sec Filings
- 3/16/26 - Form ARS
- 3/16/26 - Form DEFA14A
- 3/16/26 - Form DEF
- LXRX's page on the SEC website